REGULATORY

• Govt OKs Action Plan on Drug Resistance
  April 6, 2016

• MEXT to Set Up “Shared Facilities” for Drug Discovery, Push Open Innovation
  April 5, 2016

• MOF Panel Hears Expert’s Opinions on Opdivo Prices
  April 5, 2016

• Key Govt Panel Kicks Off Discussions on Economic, Fiscal Policy Blueprint
  April 5, 2016

• Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
  April 5, 2016

• 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
  April 4, 2016

• Xarelto under Review for Thrombocytopenia Risk
  April 4, 2016

• Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
  March 30, 2016

• MHLW OKs AZ’s Tagrisso, Novartis’s Zykadia for Lung Cancer
  March 29, 2016

• PMDA to Establish Asian Regulatory Training Center on April 1
  March 29, 2016

• Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
  March 28, 2016

• Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
  March 25, 2016

• MHLW Officially Sets Out Plan to Draw Up New Pharma Industry Vision
  March 24, 2016

• Shiozaki Hints at Delay in MHLW Report on Vaccines and Blood Product Policies
  March 24, 2016

• Ethical Hurdles for Placebo-Controlled Studies Could Be Cleared with Certain Designs: PMDA Panel
  March 23, 2016

• MHLW Alerts on Risk of Respiratory Depression for Flunitrazepam Injectables, Orders Label Revision
  March 23, 2016

• PMDA Chief Kondo Reappointed for 5th Term
  March 23, 2016

• Drug Makers Should Ponder Their Role in Community-Based Integrated Care System: MHLW Official
  March 22, 2016

• MHLW OKs Cymbalta’s New Pain Indication, Raises Caution on Its Use
  March 22, 2016

• New Basic Guidelines for Hepatitis Measures to Push IFN-Free Therapies, Hep B Vaccines
  March 18, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 278
• 279
• 280
• 281
• 282
• 283
• 284
• 285
• 286
• …
• Next ›
• 最終 »